IMC Immuron Limited
—Mkt Cap: —P/E: —1d ago
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the Unit…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value1.93M USD
Revenue (TTM)5.33M USD
Gross Profit3.29M USD
Net Income (TTM)-3.60M USD
Revenue/Share0.03 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees7
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000IMC7
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.79
EV/Revenue0.36
P/S1.51
P/B1.03
EPS (TTM)-0.01
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin65.39%
Oper. Margin-45.12%
EBITDA Margin-45.68%
Profit Margin-71.58%
ROE-64.64%
ROA-51.49%
Growth
Revenue Growth7.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.25M USD
CapEx (TTM)—
FCF Margin-26.84%
FCF Yield—
Net Debt-6.10M USD
Net Debt/EBITDA2.51
Balance Sheet
Debt/Equity0.01
Current Ratio7.26
Quick Ratio5.84
Book Value/Sh0.04 AUD
Cash/Share0.03 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:40
Split DateNov 17, 2014
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.322.85M
Float281.86M
Insiders14.35%
Institutions0.00%
Technical
SMA 500.0420 AUD
SMA 2000.0356 AUD
Beta0.47
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)194.44K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—